1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Behavioral Science Track Awards for Rapid Transition (B/START-NIDA) is sponsored by National Institute on Drug Abuse (NIDA) / NIH. This program invites newly independent investigators to submit applications for small-scale, exploratory (i.e., pilot) research projects related to NIDA's behavioral sciences mission. It provides rapid review and funding decisions.
The funding mechanism is the small grant (R03), with awards for a period of one year only and not renewable.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Newly independent investigators (cannot have been a principal investigator on a previous PHS-supported research project). Foreign organizations are not eligible. Confirm the full requirements in the official notice before applying.
The current listing shows not to exceed $50,000 in direct costs. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Behavioral Science Track Awards for Rapid Transition (B/START-NIDA) is funded by National Institute on Drug Abuse (NIDA) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) / NIH. This funding opportunity invites applications for innovative research aimed at developing and implementing interventions to prevent and treat substance use disorders (SUDs) and overdose. It encourages studies that can rapidly advance candidate solutions towards regulatory approval or clinical use, while also addressing co-morbid SUDs.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) / NIH. This Small Business Innovation Research (SBIR) funding opportunity supports small business concerns (SBC) to develop technologies for commercialization that address health-related social needs impacting Substance Use Disorders (SUD), excluding alcohol use disorder.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article